Abstract
The blood-brain barrier (BBB) efficiently restricts penetration of therapeutic agents to the brain from the periphery. Therefore, discovery of new modalities allowing for effective delivery of drugs and biomacromolecules to the central nervous system (CNS) is of great need and importance for treatment of neurodegenerative disorders. This manuscript focuses on three relatively new strategies. The first strategy involves inhibition of the drug efflux transporters expressed in BBB by Pluronic® block copolymers, which allows for the increased transport of the substrates of these transporters to the brain. The second strategy involves the design of nanoparticles conjugated with specific ligands that can target receptors in the brain microvasculature and carry the drugs to the brain through the receptor mediated transcytosis. The third strategy involves a rtificial hydrophobiz ation of peptides and proteins that facilitates the delivery of the se pe ptides a nd pr oteins ac r oss BBB. This review discusses the current state, advantages and limitations of each of the three technologies and outlines their future prospects.
Keywords: blood-brain barrier, drug efflux, drug delivery, fatty acylation, nanoge, nanoparticles, pluronic block copolymers, poloxamer.
Current Pharmaceutical Design
Title: New Technologies for Drug Delivery Across the Blood Brain Barrier
Volume: 10 Issue: 12
Author(s): A. V. Kabanov and E. V. Batrakova
Affiliation:
Keywords: blood-brain barrier, drug efflux, drug delivery, fatty acylation, nanoge, nanoparticles, pluronic block copolymers, poloxamer.
Abstract: The blood-brain barrier (BBB) efficiently restricts penetration of therapeutic agents to the brain from the periphery. Therefore, discovery of new modalities allowing for effective delivery of drugs and biomacromolecules to the central nervous system (CNS) is of great need and importance for treatment of neurodegenerative disorders. This manuscript focuses on three relatively new strategies. The first strategy involves inhibition of the drug efflux transporters expressed in BBB by Pluronic® block copolymers, which allows for the increased transport of the substrates of these transporters to the brain. The second strategy involves the design of nanoparticles conjugated with specific ligands that can target receptors in the brain microvasculature and carry the drugs to the brain through the receptor mediated transcytosis. The third strategy involves a rtificial hydrophobiz ation of peptides and proteins that facilitates the delivery of the se pe ptides a nd pr oteins ac r oss BBB. This review discusses the current state, advantages and limitations of each of the three technologies and outlines their future prospects.
Export Options
About this article
Cite this article as:
Kabanov V. A. and Batrakova V. E., New Technologies for Drug Delivery Across the Blood Brain Barrier, Current Pharmaceutical Design 2004; 10 (12) . https://dx.doi.org/10.2174/1381612043384826
DOI https://dx.doi.org/10.2174/1381612043384826 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Simple Choline Esters as Potential Anti-Alzheimer Agents
Current Pharmaceutical Design Mn (III) Tetrakis (4-Benzoic Acid) Porphyrin Protects Against Neuronal and Glial Oxidative Stress and Death After Spinal Cord Injury
CNS & Neurological Disorders - Drug Targets Sirtuin Modulators: Mechanisms and Potential Clinical Implications
Current Medicinal Chemistry Insights Into Effects of Ellagic Acid on the Nervous System: A Mini Review
Current Pharmaceutical Design Identification of Human Acetylcholinesterase Inhibitors from the Constituents of EGb761 by Modeling Docking and Molecular Dynamics Simulations
Combinatorial Chemistry & High Throughput Screening Targeting Phospho-Ser422 by Active Tau Immunotherapy in the THYTau22 Mouse Model: A Suitable Therapeutic Approach
Current Alzheimer Research Editorial: Current and Emerging Therapeutics in AD
Current Alzheimer Research Neuroprotective Effects of Quercetin: From Chemistry to Medicine
CNS & Neurological Disorders - Drug Targets Targeting Neurotrophic/Growth Factor Expression and Signaling for Antidepressant Drug Development
CNS & Neurological Disorders - Drug Targets FDG PET/MR Imaging in Major Neurocognitive Disorders
Current Alzheimer Research Patent Selections
Recent Patents on Biomarkers Commentary (Research Highlights)
CNS & Neurological Disorders - Drug Targets G Protein-Coupled Receptor Signaling Complexity in Neuronal Tissue:Implications for Novel Therapeutics
Current Alzheimer Research Occupational Complexity and Leisure Activities in Cognitive Aging
Current Psychopharmacology Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging
Current Medicinal Chemistry Potential Application of Dietary Polyphenols from Red Wine to Attaining Healthy Ageing
Current Topics in Medicinal Chemistry Can't Always Get What you Want? Try an Indirect Route you Just Might Get What you Need: A Study on Access to Genetic Data by Canadian Life Insurers
Current Pharmacogenomics and Personalized Medicine Characterization of Adipose-Derived Stem Cells: An Update
Current Stem Cell Research & Therapy Fluoride Interactions: From Molecules to Disease
Current Signal Transduction Therapy Neurodegeneration and the Heat Shock Protein 70 Machinery: Implications for Therapeutic Development
Current Topics in Medicinal Chemistry